Myostatin, follistatin and activin type II receptors are highly expressed in adenomyosis

Patrizia Carrarelli, Chih-Fen Yen, Chih‐Feng Yen, Felice Arcuri, Lucia Funghi, Claudia Tosti, Tzu‐Hao Wang, Tzu-Hao Wang, Joseph Huang, Joseph S Huang, Felice Petraglia
Fertility and sterility · 2015 · vol. 104(3) , pp. 744–752.e1 · doi:10.1016/j.fertnstert.2015.05.032 · PMID:26086422 · W1727196161
article OA: closed CC0 ⤵ 20 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-06 ⓘ

This study found that myostatin, follistatin, and activin type II receptors were highly expressed in adenomyosis tissue.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

adenomyosis

MeSH descriptors

Activin Receptors, Type II Adenomyosis Endometrium Follistatin Myostatin Activin Receptors, Type II Activin Receptors, Type II Activins Activins Adenomyosis Adenomyosis Adenomyosis Adult Case-Control Studies Endometrium Endometrium Female Follistatin Follistatin Humans

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (57)

Cited by (20)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:17:52.213533+00:00
License: CC0 · commercial use OK